Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.68 |
| ▸ | HTR2C | P28335 | 9/20 | 0.66 |
| ▸ | QDPR | P09417 | 3/20 | 0.60 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.45 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2158640 | 0.98 | HTR2C (0.69) | SIGMAR1HTR2CQDPRFTOAHR | |
| SCHEMBL19459063 | 0.85 | HTR2C (0.62) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| SCHEMBL2269930 | 0.85 | SIGMAR1 (0.67) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| Hydrochloric Acid SCHEMBL16423171 | 0.83 | HTR2C (0.68) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| SCHEMBL5539735 | 0.81 | SIGMAR1 (0.61) | SIGMAR1HTR2CQDPRFTOINPPL1 | |
| SCHEMBL1823110 | 0.81 | AHR (0.48) | SIGMAR1HTR2CQDPRAHRMAPT | |
| SCHEMBL186263 | 0.81 | HTR2C (0.57) | SIGMAR1HTR2CQDPR | |
| SCHEMBL531984 | 0.81 | SIGMAR1 (1.00) | SIGMAR1HTR2CQDPRINPPL1MAPT | |
| Hydrochloric Acid SCHEMBL1961556 | 0.80 | HTR2C (0.58) | SIGMAR1HTR2CQDPR | |
| Hydrochloric Acid SCHEMBL652812 | 0.79 | HTR2C (1.00) | SIGMAR1HTR2CQDPRINPPL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113735825-B | 1,2,3, 6-Tetrahydropyridine compound and preparation method and application thereof | 成都康弘药业集团股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-113735825-A | 1,2,3, 6-tetrahydropyridine compound and preparation method and application thereof | 成都康弘药业集团股份有限公司 | 2021-12-03 | — | — | CN | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2471774-A1 | Piperidinyl derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| US-7985861-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| EP-1963268-B1 | DISUBSTITUTED PHENYLPIPERIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB AF NEUROSEARCH SWEDEN AB (DK) | 2010-12-01 | — | — | EP | disclosed |
| EP-1345921-A1 | 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS | H. Lundbeck A/S (DK) | 2003-09-24 | — | — | EP | disclosed |
| EP-0976745-B1 | 4-TETRAHYDROPYRIDYLPYRIMIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| WO-2002051833-A1 | 3-INDOLINE DERIVATIVES USEFUL IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGIC DISORDERS | H. LUNDBECK A/S (DK) | 2002-07-04 | — | — | WO | disclosed |
| EP-1188747-A1 | PHENOXYPROPYLAMINE COMPOUNDS | Mitsubishi Pharma Corporation (JP) | 2002-03-20 | — | — | EP | disclosed |
| US-6187781-B1 | CORTICOTROPIN RELEASING FACTOR RECEPTOR ANTAGONISTS; ALZHEIMER*S, HUNTINGTON, AND PARKINSON DISEASE; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-02-13 | — | — | US | disclosed |
| EP-0976745-A1 | 4-TETRAHYDROPYRIDYLPYRIMIDINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | SIGMAR1 50/4885HTR2C 9/4885QDPR 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.